TG THERAPEUTICS INC (TGTX)

US88322Q1085 - Common Stock

22.5009  +1.23 (+5.79%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

TG THERAPEUTICS INC

NASDAQ:TGTX (7/16/2024, 2:04:02 PM)

22.5009

+1.23 (+5.79%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month41.14%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap3.48B
Shares
PE102.28
Fwd PE37.63
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TGTX Daily chart

Company Profile

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 245 full-time employees. The firm is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. The company evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Company Info

TG THERAPEUTICS INC

3020 Carrington Mill Blvd., Suite 475

Morrisville NORTH CAROLINA 10014

P: 18775758489

CEO: Michael S. Weiss

Employees: 245

Website: https://www.tgtherapeutics.com/

TGTX News

ChartMill News Image5 days ago - ChartmillIn the world of growth stocks, NASDAQ:TGTX shines as a value proposition.

Looking for growth without the hefty price tag? Consider TG THERAPEUTICS INC (NASDAQ:TGTX).

News Image19 days ago - The Motley Fool"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

Our first-ever twin bill.

News Imagea month ago - FinancialNewsMediaGlobal Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

News Imagea month ago - FN Media Group LLCGlobal Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
News Imagea month ago - TG Therapeutics, Inc.TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Fireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ET...

News Imagea month ago - TG Therapeutics, Inc.TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

Fireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET...

TGTX Twits

Here you can normally see the latest stock twits on TGTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example